Characteristics of “super responders” and “super nonresponders” to first biologic monotherapy for psoriasis: a nested case-control study
BJD, 2023.
Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group.
Read publication: BJD
Related
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for pa...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
0 Comments